Literature DB >> 1814842

Pharmacokinetics and pharmacodynamics of slow-release theophylline during treatment with nimesulide.

A Auteri1, P Blardi, F Bruni, L Domini, A L Pasqui, M Saletti, M S Verzuri, I Scaricabarozzi, G Vargui, T Di Perri.   

Abstract

The pharmacodynamic and pharmacokinetic interactions were studied between nimesulide, a recently introduced non-steroidal anti-inflammatory drug, and theophylline, another highly protein-bound drug, in patients who were receiving slow-release theophylline for a chronic airflow-obstruction and who also needed anti-inflammatory treatment. A good tolerability was demonstrated of the two drugs association and there was an absence of pharmacodynamic interaction, as shown by lung function parameters, assayed before and after the coinciding nimesulide association. The pharmacokinetics of nimesulide and 4-hydroxy-nimesulide (its active metabolite) were not modified, in agreement with data shown by other authors. On the contrary, there was a slight alteration of theophylline pharmacokinetics, yet neither clinically nor biologically significant, probably due to an enzymatic induction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814842

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  5 in total

Review 1.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

2.  Nimesulide binding to components within blood.

Authors:  F Bree; P Nguyen; S Urien; E Albengres; A Macciocchi; J P Tillement
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 3.  Drug interactions with nimesulide.

Authors:  E Perucca
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of nimesulide.

Authors:  A Bernareggi
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 5.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.